Breakthrough Alzheimer's Drug Lecanemab Shows Potential to Delay Disease Progression by Over Eight Years
New data presented at a major international conference reveals that the Alzheimer's drug lecanemab (Leqembi) could dramatically slow disease progression by over eight years for certain patients, offering a far more optimistic outlook than previously understood. These groundbreaking findings, which highlight the profound impact of early intervention and include the development of a convenient at-home injectable version, underscore the critical need for early diagnosis despite concerns over the drug's high annual cost.
